Ibrutinib is a targeted therapy that belongs to a class of drugs known as Bruton's tyrosine kinase (BTK) inhibitors. By blocking the BTK protein, Ibrutinib prevents cancer cells from growing and dividing. This action makes it effective in treating cancers that depend on the B-cell receptor signaling pathway, such as CLL and MCL.
The Need for Ibrutinib
Blood cancers can significantly impact...
English 
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek
Vietnamese (Vietnam)
Hindi (India)
Japanese (Japan)
Khmer (Cambodia)
Korean (Korea)
Lao
Burmese (Myanmar)
Thai (Thailand)
Chinese (China)
Chinese (Taiwan)